



SPECIAL SYMPOSIUM:



CHOOSING AN OMICS PLATFORM FOR YOUR CLINICAL TRIAL

Thursday, May 11, 8:00-10:05 am PT Grand Ballroom A

A round robin of our colleagues from industry will share concise overviews of their OMICs platforms at this special event. Visit them at exhibit tables in the Grand Ballroom Foyer for one-on-one questions and conversations on both Thursday and Friday.

8:00am: Welcome by Lee Ellis, MD, FASCO, SWOG Vice Chair for Translational Medicine

Guardant Health (8:05-8:20)

Justin Odegaard, MD, PhD, *Vice President of Clinical Development*

Veracyte (8:20-8:35)

Ewan Gibb, PhD, *Principal Scientist, Bladder Cancer Lead*

Foundation Medicine (8:35-8:50)

Mia Levy, MD, PhD, *Chief Medical Officer*

Exact Sciences (8:50-9:05)

Christy Russell, MD, *Vice President of Medical Affairs, Precision Oncology*

BostonGene (9:05-9:20)

Patrick Clayton, PhD, *Business Development and Alliance Manager*

Caris Life Sciences (9:20-9:35)

Ari VanderWalde, MD, MPH, FACP, *Vice President of Clinical Development, Precision Oncology Alliance*

Tempus (9:35-9:50)

Calvin Chao, MD, *Senior Vice President of Medical Affairs*

Natera (9:50-10:05)

Adam ElNaggar, MD, FASCO, *Medical Director, Oncology*

10:05am – Closing and thank you!

Please visit the meeting exhibits to follow up and learn more.

ABOUT THE PLATFORMS

BostonGene's mission is to power healthcare's transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce overall cost of cancer care. BostonGene's tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene's tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at <http://www.BostonGene.com>.

Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).

BostonGene



EXACT SCIENCES

A leading provider of cancer screening and diagnostic tests, **Exact Sciences** relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to support patients before and throughout their cancer diagnosis and treatment. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at exactsciences.com, follow Exact Sciences on **Twitter @ExactSciences**, or find Exact Sciences on Facebook.



Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit www.FoundationMedicine.com.



Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.



Natera is a leader in molecular residual disease (MRD) testing for solid tumors. Natera has developed the Signatera assay, a personalized, tumor-informed plasma assay, to help identify early signals of recurrence, progression, and response sooner than conventional methods. In clinical trials, Signatera could help to optimize patient selection and support early prediction of treatment response. Signatera has been studied in >40 peer reviewed publications and >100 presentations, is covered by Medicare and commercial payors for multiple indications, with over 250,000 tests performed to date. Additionally, Natera offers comprehensive genomic profiling and hereditary cancer testing to support a range of clinical and clinical trial testing needs.

"TEMPUS

Tempus is focused on building the leading AI-enabled Intelligent Diagnostic platform in the world. We are an integrated partner offering a broad range of DNA and RNA sequencing services. We are improving patient care through comprehensive testing, clinical trial matching, and deep research data that powers scientific discovery. Through our scientific publications and research projects, we are accelerating and transforming personalized patient care. We generate insights at scale to help doctors make better decisions, drug companies make better drugs, and patients live longer and healthier lives.



Veracyte is a global diagnostics company whose vision is to transform cancer care for patients worldwide. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and with selecting appropriate treatment.